arrow
K

Kaïssa Ouali

gustave roussy
H指数:6
被引数:169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials

基于早期临床试验中接受免疫检查点阻断治疗患者的预后评分的开发与外部验证:与不良结局相关的评分

2026-07-010
PRE
Outcomes of patients treated by FGFR inhibitors according to alteration types: an agnostic monocentric retrospective cohort

FGFR抑制剂治疗患者的结局与变异类型的关系:一项无偏倚的单中心回顾性队列研究

2026-06-190
PRE
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study

早期肿瘤学临床试验纳入患者中的急性肾损伤,AKITEP研究的结果

2026-05-260
PRE
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials

年龄不影响抗体药物偶联物的疗效,但与在早期临床试验中入组的癌症患者发生高等级不良事件相关。

2025-05-160
PRE
Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry

T细胞接合剂作为癌症免疫疗法治疗患者的感染并发症:一项来自REISAMIC登记研究的描述性研究

2025-04-010
PRE
DETECTION OF CIRCULATING TUMOR DNA (CTDNA) IN CEREBROSPINAL FLUID (CSF) IN PATIENTS WITH GLIOBLASTOMA TREATED IN PHASE I CLINICAL TRIAL
2024-11-110
PRE
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review

T细胞接合器作为抗癌免疫疗法引起的反应和不良事件,全面综述

2024-07-011
PRE
Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome

与免疫检查点抑制剂、治疗管理和结果相关的药物诱导的自身免疫性溶血性贫血

2024-04-200
PRE
Subcutaneous fat mass predicts progression-free survival in patients treated with antibody-drug-conjugates in early-phase clinical trials
2024-03-220
PRE
Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal single-cell analysis of patient tumors identifies biological correlates of response to PARP inhibitors and anti-PD-L1 therapy
2024-03-220
PRE
The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
2024-01-160
PRE
Antibody drug conjugates in older patients: State of the art

老年患者的抗体药物结合物: 最新技术

2024-01-014
OAAI
Factors associated with primary resistance to immune checkpoint blockade in early phase clinical trials
2023-12-010
PRE